MCID: PRM013
MIFTS: 57

Premature Menopause

Categories: Endocrine diseases, Reproductive diseases

Aliases & Classifications for Premature Menopause

MalaCards integrated aliases for Premature Menopause:

Name: Premature Menopause 12 12 15 17 70
Premature Ovarian Failure 12 73 36 29 6 15
Primary Ovarian Insufficiency 12 42 44 17
Hypergonadotropic Hypogonadism 12 54 6
Premature Ovarian Insufficiency 12 6
Menopause - Premature 12
Menopause, Premature 44
Menopause Premature 54
Menopause Praecox 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10787 DOID:5426
KEGG 36 H00627
ICD9CM 34 256.31
SNOMED-CT 67 154713003 237788002
ICD10 32 E28.3 E28.31
UMLS 70 C0025322 C0085215

Summaries for Premature Menopause

MedlinePlus : 42 What is primary ovarian insufficiency (POI)? Primary ovarian insufficiency (POI), also known as premature ovarian failure, happens when a woman's ovaries stop working normally before she is 40. Many women naturally experience reduced fertility when they are about 40 years old. They may start getting irregular menstrual periods as they transition to menopause. For women with POI, irregular periods and reduced fertility start before the age of 40. Sometimes it can start as early as the teenage years. POI is different from premature menopause. With premature menopause, your periods stop before age 40. You can no longer get pregnant. The cause can be natural or it can be a disease, surgery, chemotherapy, or radiation. With POI, some women still have occasional periods. They may even get pregnant. In most cases of POI, the cause is unknown. What causes primary ovarian insufficiency (POI)? In about 90 percent of cases, the exact cause of POI is unknown. Research shows that POI is related to problems with the follicles. Follicles are small sacs in your ovaries. Your eggs grow and mature inside them. One type of follicle problem is that you run out of working follicles earlier than normal. Another is that the follicles are not working properly. In most cases, the cause of the follicle problem is unknown. But sometimes the cause may be Genetic disorders such as Fragile X syndrome and Turner syndrome A low number of follicles Autoimmune diseases, including thyroiditis and Addison disease Chemotherapy or radiation therapy Metabolic disorders Toxins, such as cigarette smoke, chemicals, and pesticides Who is at risk for for primary ovarian insufficiency (POI)? Certain factors can raise a woman's risk of POI: Family history. Women who have a mother or sister with POI are more likely to have it. Genes. Some changes to genes and genetic conditions put women at higher risk for POI. For example, women Fragile X syndrome or Turner syndrome are at higher risk. Certain diseases, such as autoimmune diseases and viral infections Cancer treatments, such as chemotherapy and radiation therapy Age. Younger women can get POI, but it becomes more common between the ages of 35-40. What are the symptoms of primary ovarian insufficiency (POI)? The first sign of POI is usually irregular or missed periods. Later symptoms may be similar to those of natural menopause: Hot flashes Night sweats Irritability Poor concentration Decreased sex drive Pain during sex Vaginal dryness For many women with POI, trouble getting pregnant or infertility is the reason they go to their health care provider. What other problems can primary ovarian insufficiency (POI) cause? Since POI causes you to have lower levels of certain hormones, you are at greater risk for other health conditions, including Anxiety and depression. Hormonal changes caused by POI can contribute to anxiety or lead to depression. Dry eye syndrome and eye surface disease. Some women with POI have one of these eye conditions. Both can cause discomfort and may lead to blurred vision. If not treated, these conditions can cause permanent eye damage. Heart disease. Lower levels of estrogen can affect the muscles lining the arteries and can increase the buildup of cholesterol in the arteries. These factors increase your risk of atherosclerosis (hardening of the arteries). Infertility. Low thyroid function. This problem also is called hypothyroidism. The thyroid is a gland that makes hormones that control your body's metabolism and energy level. Low levels thyroid hormones can affect your metabolism and can cause very low energy, mental sluggishness, and other symptoms. Osteoporosis. The hormone estrogen helps keep bones strong. Without enough estrogen, women with POI often develop osteoporosis. It is a bone disease that causes weak, brittle bones that are more likely to break. How is primary ovarian insufficiency (POI) diagnosed? To diagnose POI, your health care provider may do A medical history, including asking whether you have relatives with POI A pregnancy test, to make sure that you are not pregnant A physical exam, to look for signs of other disorders which could be causing your symptoms Blood tests, to check for certain hormone levels. You may also have a blood test to do a chromosome analysis. A chromosome is the part of a cell that contains genetic information. A pelvic ultrasound, to see whether or not the ovaries are enlarged or have multiple follicles How is primary ovarian insufficiency (POI) treated? Currently, there is no proven treatment to restore normal function to a woman's ovaries. But there are treatments for some of the symptoms of POI. There are also ways to lower your health risks and treat the conditions that POI can cause: Hormone replacement therapy (HRT). HRT is the most common treatment. It gives your body the estrogen and other hormones that your ovaries are not making. HRT improves sexual health and decreases the risks for heart disease and osteoporosis. You usually take it until about age 50; that's about the age when menopause usually begins. Calcium and vitamin D supplements. Because women with POI are at higher risk for osteoporosis, you should take calcium and vitamin D every day. In vitro fertilization (IVF). If you have POI and you wish to become pregnant, you may consider trying IVF. Regular physical activity and a healthy body weight. Getting regular exercise and controlling your weight can lower your risk for osteoporosis and heart disease. Treatments for associated conditions. If you have a condition that is related to POI, it is important to treat that as well. Treatments may involve medicines and hormones. NIH: National Institute of Child Health and Human Development

MalaCards based summary : Premature Menopause, also known as premature ovarian failure, is related to premature ovarian failure 1 and perrault syndrome, and has symptoms including pelvic pain An important gene associated with Premature Menopause is STAG3 (Stromal Antigen 3), and among its related pathways/superpathways are Ovarian steroidogenesis and DNA Damage. The drugs Ethinyl Estradiol and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include breast, ovary and bone, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Disease Ontology : 12 An ovarian disease where ovaries do not produce estrogen despite high levels of circulating gonadotropins in women under 40.

KEGG : 36 Premature ovarian failure (POF) is characterized by amenorrhea before the age of 40 years with elevated levels of gonadotrophin (LH and FSH) and low levels of gonadal hormones (estrogens and inhibins). The causes of POF can be categorized into genetic and environmental mechanisms. X chromosome defects such as Turner syndrome or trisomy X as well as many genes including BMP15 andFMR1 are associated with POF development. For the environmental causes, medical intervention including surgeries and chemotherapies may lead to POF. Autoimmune ovarian failure consists another large category of POF.

Wikipedia : 73 Primary ovarian insufficiency (POI) (also called premature ovarian insufficiency, premature menopause,... more...

Related Diseases for Premature Menopause

Diseases related to Premature Menopause via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 premature ovarian failure 1 32.9 STAG3 SGO2 RAD54L PMM2 NOBOX JAK2
2 perrault syndrome 32.4 SGO2 NOBOX EIF2B2
3 galactosemia i 31.3 PMM2 NOBOX GALT
4 fanconi anemia, complementation group a 31.0 STAG3 POLG NBN MSH4 ERCC1 CHEK2
5 mayer-rokitansky-kuster-hauser syndrome 30.7 WT1 TP63 GALT
6 ovarian disease 30.6 STAG3 NOBOX GALT CYP19A1
7 spermatogenic failure 3 30.4 STAG3 MSH4
8 leukemia, acute myeloid 30.4 WT1 JAK2 INSL6 CHEK2 BRDT
9 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 11.9
10 premature ovarian failure 10 11.8
11 premature ovarian failure 11 11.8
12 premature ovarian failure 2b 11.7
13 premature ovarian failure 3 11.7
14 premature ovarian failure 6 11.7
15 premature ovarian failure 2a 11.7
16 premature ovarian failure 17 11.7
17 osteosclerosis with ichthyosis and premature ovarian failure 11.7
18 moyamoya disease 4 with short stature, hypergonadotropic hypogonadism, and facial dysmorphism 11.6
19 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 11.6
20 leydig cell hypoplasia 11.5
21 genetic non-acquired premature ovarian failure 11.5
22 primary ovarian insufficiency 9 11.5
23 premature ovarian failure 18 11.5
24 primary ovarian insufficiency 2a 11.5
25 primary ovarian insufficiency 2b 11.5
26 primary ovarian insufficiency 3 11.5
27 primary ovarian insufficiency 4 11.5
28 primary ovarian insufficiency 5 11.5
29 primary ovarian insufficiency 6 11.5
30 primary ovarian insufficiency 7 11.5
31 primary ovarian insufficiency 8 11.5
32 primary ovarian insufficiency 10 11.5
33 primary ovarian insufficiency 11 11.5
34 primary ovarian insufficiency 12 11.5
35 primary ovarian insufficiency 13 11.5
36 primary ovarian insufficiency 14 11.5
37 primary ovarian insufficiency 15 11.5
38 primary ovarian insufficiency 16 11.5
39 primary ovarian insufficiency 17 11.5
40 leydig cell hypoplasia, type i 11.4
41 hypogonadism-cataract syndrome 11.4
42 hypergonadotropic hypogonadism and partial alopecia 11.4
43 marinesco-sjogren syndrome 11.3
44 cerebellar ataxia and hypergonadotropic hypogonadism 11.3
45 alopecia-mental retardation syndrome with convulsions and hypergonadotropic hypogonadism 11.3
46 retinal dystrophy with or without extraocular anomalies 11.3
47 leukoencephalopathy, progressive, with ovarian failure 11.2
48 acquired premature ovarian failure 11.2
49 non-acquired premature ovarian failure 11.2
50 short stature, microcephaly, and endocrine dysfunction 11.2

Graphical network of the top 20 diseases related to Premature Menopause:



Diseases related to Premature Menopause

Symptoms & Phenotypes for Premature Menopause

UMLS symptoms related to Premature Menopause:


pelvic pain

GenomeRNAi Phenotypes related to Premature Menopause according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-2 9.35 JAK2
2 Decreased substrate adherent cell growth GR00193-A-3 9.35 BRDT CHEK2 JAK2
3 Decreased substrate adherent cell growth GR00193-A-4 9.35 CHEK2
4 Increased ID2::GFP protein expression GR00211-A 8.62 NBN TP63

MGI Mouse Phenotypes related to Premature Menopause:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6
2 endocrine/exocrine gland MP:0005379 10.33 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6
3 homeostasis/metabolism MP:0005376 10.25 BRDT CHEK2 CYP19A1 ERCC1 GALT JAK2
4 hematopoietic system MP:0005397 10.17 CHEK2 CYP19A1 EIF2B2 ERCC1 JAK2 NBN
5 mortality/aging MP:0010768 10.17 CHEK2 EIF2B2 ERCC1 GALT JAK2 NBN
6 immune system MP:0005387 10.15 CHEK2 CYP19A1 ERCC1 GALT JAK2 NBN
7 reproductive system MP:0005389 9.83 BRDT CHEK2 CYP19A1 ERCC1 GALT INSL6
8 muscle MP:0005369 9.8 CYP19A1 ERCC1 PMM2 POLG PREPL TP63
9 neoplasm MP:0002006 9.7 CHEK2 ERCC1 JAK2 NBN POLG TP63
10 skeleton MP:0005390 9.28 BRDT CYP19A1 ERCC1 JAK2 PMM2 POLG

Drugs & Therapeutics for Premature Menopause

Drugs for Premature Menopause (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
2
Lactitol Approved, Investigational Phase 4 585-86-4 157355
3
Norethindrone Approved Phase 4 68-22-4 6230
4
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
5
Lenograstim Approved, Investigational Phase 4 135968-09-1
6
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
7
Molgramostim Investigational Phase 4 99283-10-0
8 Contraceptive Agents Phase 4
9 Contraceptives, Oral Phase 4
10 Hormone Antagonists Phase 4
11 Norinyl Phase 4
12 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
13 Norethindrone Acetate Phase 4
14
Metronidazole Approved Phase 3 443-48-1 4173
15
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
16
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
17
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 5881
18
Black cohosh Experimental Phase 3
19 Antineoplastic Agents, Hormonal Phase 2, Phase 3
20 Triptorelin Pamoate Phase 2, Phase 3
21 Immunologic Factors Phase 2, Phase 3
22 Adjuvants, Immunologic Phase 2, Phase 3
23 DHEA (Dehydroepiandrosterone) Phase 2, Phase 3
24 Epinephryl borate Phase 2, Phase 3
25 Androgens Phase 2, Phase 3
26 Phytoestrogens Phase 3
27
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
28
Goserelin Approved Phase 2 65807-02-5 47725 5311128
29
Testosterone Approved, Investigational Phase 1, Phase 2 58-22-0 6013
30
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
31
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
32
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
33 Anabolic Agents Phase 1, Phase 2
34 Testosterone 17 beta-cypionate Phase 1, Phase 2
35 Mitogens Phase 1, Phase 2
36
Vitamin D Approved, Nutraceutical, Vet_approved Phase 1 1406-16-2
37
Vitamin D3 Approved, Nutraceutical Phase 1 67-97-0 5280795 6221
38 Calcium, Dietary Phase 1
39 Estrogens, Conjugated (USP) Phase 1
40 Trace Elements Phase 1
41 Nutrients Phase 1
42 Micronutrients Phase 1
43 Vitamins Phase 1
44 Calciferol Phase 1
45
Calcium Nutraceutical Phase 1 7440-70-2 271
46
Heparin Approved, Investigational 9005-49-6 772 9812414
47
Estrone Approved 53-16-7 5870
48
Prednisone Approved, Vet_approved 53-03-2 5865
49
Chromium Approved 7440-47-3 27668
50
Molybdenum Approved 7439-98-7 185498

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial Unknown status NCT02783937 Phase 4 Saline
2 Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure Unknown status NCT01853501 Phase 4
3 Comparison of Standard and Physiologic Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure and the Assessment of Skeletal, Cardiovascular and Reproductive Parameters Completed NCT00732693 Phase 4 Ethinylestradiol / Norethisterone;Estradiol / Progesterone
4 The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
5 Estrogen Dosing in Turner Syndrome:Pharmacology & Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
6 Autologous Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Patients. Pilot Study ASCOT-2 Not yet recruiting NCT03535480 Phase 4 G-CSF
7 Estrogen Replacement in Hypogonadal Girls Treated With GH: Differential Effects of Mode of Estrogen Delivery Completed NCT00140998 Phase 3 17 beta estradiol
8 A Prospective Open Randomized Trial on the Efficacy of Gonadotropin-releasing Hormone Agonist Depot-Triptorelin- to Prevent Chemotherapy Induced Premature Ovarian Failure in Lymphoma Patients. Completed NCT01160315 Phase 2, Phase 3 Triptorelin;Norethisterone acetate
9 4-step ASCOT in POI Women to Promote Follicular Rescue Recruiting NCT04475744 Phase 3 G-CSF treatment for Bone marrow derived stem cell Mobilization
10 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Recruiting NCT03568708 Phase 3 Transdermal Estrogen
11 Investigating Reactivation of Ovarian Function Following Autologous PRP Intra-ovarian Infusion in POI Patients Recruiting NCT04031456 Phase 2, Phase 3
12 A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Premature Ovarian Failure (POF). Terminated NCT00948857 Phase 2, Phase 3
13 A Randomized Double Blinded Trail of DHEA Supplementation for Treatment of Couples With Normal Hysterosalpingogram and Normal Semen Analysis and Evidence of Premature Ovarian Aging (POA). Terminated NCT00650754 Phase 2, Phase 3
14 Effect of Exercise and Exercise + Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
15 Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency Withdrawn NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
16 Evaluate the Safety and Feasibility of Intra-ovarian Injection of Autologous Adipose Derived Mesenchymal Stromal Cells (ADMSC) in Women With Premature Ovarian Failure(POF) Unknown status NCT02603744 Phase 1, Phase 2
17 Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure Unknown status NCT02043743 Phase 1, Phase 2
18 Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Unknown status NCT02062931 Phase 1, Phase 2
19 A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure Unknown status NCT01742533 Phase 1, Phase 2 Hormone Replacement Therapy
20 Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI) Unknown status NCT03033277 Phase 1, Phase 2
21 Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate
22 Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial Completed NCT02794948 Phase 1, Phase 2
23 "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Completed NCT02372474 Phase 1, Phase 2
24 Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients Completed NCT04536467 Phase 2 Goserelin;Chemotherapy
25 Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure (POF) Completed NCT02151890 Phase 1, Phase 2
26 The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) With Injectable Collagen Scaffold Transplantation in Woman With Premature Ovarian Failure (POF) Completed NCT02644447 Phase 1, Phase 2
27 Hormone Replacement in Young Women With Premature Ovarian Failure Completed NCT00001951 Phase 2 TMTDS
28 A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization Recruiting NCT01662466 Phase 1, Phase 2 Testosterone cream (0.5mg per gram);Placebo
29 Transplantation of Specific Populations of Bone Marrow-Derived Stem Cells and Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure. Active, not recruiting NCT03069209 Phase 1, Phase 2
30 Platelet Rich Plasma Ovarian in Vitro Activation and Stem Cells Transplantation In Women With Ovarian Failure Enrolling by invitation NCT04009473 Phase 1, Phase 2
31 Clinical Study on the Safety and Effectiveness of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency Suspended NCT03816852 Phase 2
32 Effect of Transdermal Estradiol Replacement Therapy on Ovulation Rate in Women With Premature Ovarian Failure: A Randomized, Placebo-Controlled Trial Withdrawn NCT00370019 Phase 2 Estradiol/Medroxyprogesterone acetate
33 Autologous Very Small Embryonic-like Stem Cells(VSELs) for Premature Ovarian Failure Withdrawn NCT03985462 Phase 1, Phase 2
34 Phase 1, Open-Label, Randomized, Single-Dose, Crossover Bioequivalence And Food Effect Study For A New Formulation Of Premarin Compared With A Reference Tablet In Japanese Healthy Postmenopausal Women Completed NCT01436513 Phase 1 Premarin reference tablet (fasted);Premarin new tablet (fasted);Premarin reference tablet (fed);Premarin new tablet (fed)
35 The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition Completed NCT01141972 Phase 1
36 Autologous Platelet-Rich Plasma (PRP) Infusions and Biomarkers of Ovarian Rejuvenation and Aging Mitigation Completed NCT03178695 Phase 1
37 International Peace Maternity and Child Health Hospital (IPMCH) Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, China Recruiting NCT02912104 Phase 1
38 The Use of Expanded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans: Phase I Clinical Trial Recruiting NCT04815213 Phase 1
39 Safety Study of Human Embryonic Stem Cell Derived Mesenchymal Stem Cell (MSC)-Like Cells Transplantation in Women With Primary Ovarian Insufficiency (POI) Recruiting NCT03877471 Phase 1
40 Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency: An Exporatory Pilot Study. Terminated NCT02181595 Phase 1
41 Autologous Bone Marrow Transplantation for Treatment of Premature Ovarian Insufficiency Unknown status NCT02779374
42 Clinical Study of Minimally Invasive Implantation of Human Amniotic Epithelial Cells in the Treatment of Premature Ovarian Insufficiency Unknown status NCT03207412
43 in Vivo Activation of Ovarian Cortex in Premature Ovarian Insufficiency Unknown status NCT03034616
44 Ovarian Histopathology and Laparoscopic Assessment of Premature Ovarian Failure and Its Relation to Thyroid Dysfunction Unknown status NCT03412487
45 Premature Ovarian Failure : Genetic and Physiopathologic Analysis Unknown status NCT00780897
46 Phenotyping and Genotyping of Women Presenting With Ovarian Dysfunction Associated With a Hypergonadotropic Hypo-estrogenic Hormonal Status (WHO III) and Their First and Second Degree Relatives Unknown status NCT01411644
47 Development a Predictive Nomogram for Primary Ovarian Insufficiency Unknown status NCT02795000
48 Perception and Attitude Toward Estrogen Therapy Among Operated Women With Premature or Immature Menopause Unknown status NCT00173550
49 Cost Effectiveness of Two Different Strategies to Implement the NVOG Guideline Programme on Subfertility Unknown status NCT00119925
50 The Role of Inactive Follicle Stimulating Hormone in Ovarian Dysfunction in Galactosemia Unknown status NCT00619333 follitropin and lutropin

Search NIH Clinical Center for Premature Menopause

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Angelica sinensis preparation
Black Cohosh Extract
Chlorotrianisene
Estradiol
Estradiol acetate
estradiol cypionate
ESTRADIOL PWDR
estradiol valerate
Estrogens
Estrogens, Conjugated (USP)
Estrogens, Esterified (USP)
Estrone
estropipate
Ethinyl Estradiol
polyestradiol
polyestradiol phosphate
Quinestrol
Sodium estrone sulfate
synthetic conjugated estrogens, A
synthetic conjugated estrogens, B

Cochrane evidence based reviews: primary ovarian insufficiency

Genetic Tests for Premature Menopause

Genetic tests related to Premature Menopause:

# Genetic test Affiliating Genes
1 Premature Ovarian Failure 29

Anatomical Context for Premature Menopause

MalaCards organs/tissues related to Premature Menopause:

40
Breast, Ovary, Bone, Eye, Thyroid, Heart, Bone Marrow

Publications for Premature Menopause

Articles related to Premature Menopause:

(show top 50) (show all 3114)
# Title Authors PMID Year
1
Genomic analysis using high-resolution single-nucleotide polymorphism arrays reveals novel microdeletions associated with premature ovarian failure. 61 6
21256485 2011
2
Rare missense variant in MSH4 associated with primary gonadal failure in both 46, XX and 46, XY individuals. 6
33448284 2021
3
Identification of variants in pleiotropic genes causing "isolated" premature ovarian insufficiency: implications for medical practice. 6
29706645 2018
4
Homozygous mutations in C14orf39/SIX6OS1 cause non-obstructive azoospermia and premature ovarian insufficiency in humans. 42
33508233 2021
5
The p63 C-terminus is essential for murine oocyte integrity. 42
33452256 2021
6
Clinical analysis of human umbilical cord mesenchymal stem cell allotransplantation in patients with premature ovarian insufficiency. 42
33124125 2020
7
Premature menopause in patients with BRCA1 gene mutation. 54 61
16773440 2006
8
Ginsenoside Rg1 ameliorates reproductive function injury in C57BL/6J mice induced by di-N-butyl-phthalate. 61
33331133 2021
9
Xeroderma Pigmentosum: A Model for Human Premature Aging. 61
33436302 2021
10
Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity. 61
33465522 2021
11
Hormone replacement therapy and cervical cancer: a systematic review of the literature. 61
33236658 2021
12
Recent Advancements in Engineered Biomaterials for the Regeneration of Female Reproductive Organs. 61
33797052 2021
13
Sodium alginate-bioglass-encapsulated hAECs restore ovarian function in premature ovarian failure by stimulating angiogenic factor secretion. 61
33794993 2021
14
Protective Effects of Puerarin on Premature Ovarian Failure via Regulation of Wnt/β-catenin Signaling Pathway and Oxidative Stress. 61
32996063 2021
15
Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. 61
33582778 2021
16
Predicting chemotherapy-induced menopause using baseline and post-chemotherapy anti-Müllerian hormone levels: Results of a pilot study. 61
33660428 2021
17
A narrative review of platelet-rich plasma (PRP) in reproductive medicine. 61
33723748 2021
18
Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge. 61
33807517 2021
19
The Genetic and Clinical Features of FOXL2-Related Blepharophimosis, Ptosis and Epicanthus Inversus Syndrome. 61
33806295 2021
20
Adult Stem Cell Therapy for Premature Ovarian Failure: From Bench to Bedside. 61
33427039 2021
21
Human Umbilical Cord Mesenchymal Stem Cells Improve Ovarian Function in Chemotherapy-Induced Premature Ovarian Failure Mice Through Inhibiting Apoptosis and Inflammation via a Paracrine Mechanism. 61
33751459 2021
22
Human mesenchymal stem cell treatment of premature ovarian failure: new challenges and opportunities. 61
33658073 2021
23
Melatonin provides protection against cisplatin-induced ovarian damage and loss of fertility in mice. 61
33388265 2021
24
In vitro activation of cryopreserved ovarian tissue: A single-arm meta-analysis and systematic review. 61
33485262 2021
25
Hashimoto's thyroiditis worsens ovaries in polycystic ovary syndrome patients compared to Anti-Müllerian hormone levels. 61
33750377 2021
26
Energy sensors and reproductive hypothalamo-pituitary ovarian axis (HPO) in female mammals: Role of mTOR (mammalian target of rapamycin), AMPK (AMP-activated protein kinase) and SIRT1 (Sirtuin 1). 61
33301839 2021
27
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women. 61
33161765 2021
28
Thyroid autoimmunity is associated with higher risk of premature ovarian insufficiency-a nationwide Health Insurance Research Database study. 61
33569594 2021
29
Myasthenia gravis and premature ovarian failure - a causal link. 61
33555605 2021
30
Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial. 61
32907814 2021
31
The Emerging Key Role of Klotho in the Hypothalamus-Pituitary-Ovarian Axis. 61
32783104 2021
32
An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects. 61
33632047 2021
33
Clonal Hematopoiesis and Premature Menopause: Unexpected Liaison. 61
33523729 2021
34
Exosomes as Biomarkers for Female Reproductive Diseases Diagnosis and Therapy. 61
33671587 2021
35
Sexuality- and Fertility-Related Issues in Women after Allogeneic Hematopoietic Stem Cell Transplantation. 61
33789835 2021
36
Receptor tyrosine kinases-instructed release of its inhibitor from hydrogel to delay ovarian aging. 61
33248720 2021
37
Preconception genome medicine: current state and future perspectives to improve infertility diagnosis and reproductive and health outcomes based on individual genomic data. 61
33197264 2021
38
Bone Marrow-Derived Mesenchymal Stem Cells Reverse Radiotherapy-Induced Premature Ovarian Failure: Emphasis on Signal Integration of TGF-β, Wnt/β-Catenin and Hippo Pathways. 61
33594662 2021
39
Loss of ESRP1 blocks mouse oocyte development and leads to female infertility. 61
33318146 2021
40
Denosumab-Induced Immune Hepatitis. 61
33466886 2021
41
Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. 61
33300669 2021
42
The risk and added values of the atherosclerotic cardiovascular risk enhancers on prediction of cardiovascular events: Tehran lipid and glucose study. 61
33407576 2021
43
Age of Natural Menopause Among Jordanian Women and Factors Related to Premature and Early Menopause. 61
33500673 2021
44
Fertility preservation in women for medical and social reasons: Oocytes vs ovarian tissue. 61
32800711 2021
45
Premature and Early Menopause in Relation to Cardiovascular Disease. 61
33511582 2021
46
Genetic Determinants of Premature Menopause in A Mashhad Population Cohort. 61
33497044 2021
47
The epidemiology of atrial fibrillation in Chinese postmenopausal women and its association with age of menopause. 61
33308621 2021
48
Acquired pure red cell aplasia and T cell large granular lymphocytic leukaemia in patients with autoimmune polyglandular syndrome type 1. 61
33468135 2021
49
Association of premature menopause with incident pulmonary hypertension: A cohort study. 61
33690615 2021
50
Association of menopause with risk of carotid artery atherosclerosis. 61
33308625 2021

Variations for Premature Menopause

ClinVar genetic disease variations for Premature Menopause:

6 (show top 50) (show all 345)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NBN NM_002485.4(NBN):c.871C>T (p.Gln291Ter) SNV Pathogenic 495048 rs1554563822 GRCh37: 8:90982617-90982617
GRCh38: 8:89970389-89970389
2 EIF2B2 NM_014239.4(EIF2B2):c.514C>T (p.Arg172Ter) SNV Pathogenic 495049 rs758398310 GRCh37: 14:75471520-75471520
GRCh38: 14:75004817-75004817
3 EIF2B2 NM_014239.4(EIF2B2):c.818A>G (p.Lys273Arg) SNV Pathogenic 495050 rs113994016 GRCh37: 14:75473404-75473404
GRCh38: 14:75006701-75006701
4 PREPL NM_001171603.1(PREPL):c.881_955delinsTTTTA (p.Lys294fs) Indel Pathogenic 619046 rs1558502635 GRCh37: 2:44566300-44566374
GRCh38: 2:44339161-44339235
5 overlap with 2 genes Deletion Pathogenic 619047 GRCh37: 2:44504991-44580502
GRCh38: 2:44277853-44353364
6 TP63 NM_003722.5(TP63):c.1780C>T (p.Arg594Ter) SNV Pathogenic 619065 rs900140738 GRCh37: 3:189612028-189612028
GRCh38: 3:189894239-189894239
7 TP63 NM_003722.5(TP63):c.1794G>A (p.Trp598Ter) SNV Pathogenic 619066 rs1560311010 GRCh37: 3:189612042-189612042
GRCh38: 3:189894253-189894253
8 PEX6 NM_000287.4(PEX6):c.371T>C (p.Leu124Pro) SNV Pathogenic 869197 GRCh37: 6:42946518-42946518
GRCh38: 6:42978780-42978780
9 MSH4 NM_002440.4(MSH4):c.2261C>T (p.Ser754Leu) SNV Pathogenic 869115 rs377712900 GRCh37: 1:76356415-76356415
GRCh38: 1:75890730-75890730
10 ERCC1 NM_001983.4(ERCC1):c.466C>T (p.Arg156Trp) SNV Pathogenic 978472 GRCh37: 19:45922415-45922415
GRCh38: 19:45419157-45419157
11 overlap with 2 genes GRCh38/hg38 2p13.1(chr2:73601366-73673202)x1 copy number loss Pathogenic 221691 GRCh37: 2:73828493-73900329
GRCh38: 2:73601366-73673202
12 overlap with 30 genes GRCh37/hg19 8p23.1(chr8:8131816-12249050)x1 copy number loss Pathogenic 221719 GRCh37: 8:8131816-12249050
GRCh38:
13 SGO2 NM_152524.6(SGO2):c.1451_1452GA[1] (p.Glu485fs) Microsatellite Pathogenic 375672 rs1057519602 GRCh37: 2:201436519-201436520
GRCh38: 2:200571796-200571797
14 RAD54L NM_003579.4(RAD54L):c.1138C>T (p.Arg380Trp) SNV Pathogenic 929734 GRCh37: 1:46736426-46736426
GRCh38: 1:46270754-46270754
15 BRDT NM_001726.4(BRDT):c.1538del (p.Asp513fs) Deletion Pathogenic 929738 GRCh37: 1:92446523-92446523
GRCh38: 1:91980966-91980966
16 STAG3 NM_001282717.2(STAG3):c.1069C>T (p.Arg357Ter) SNV Pathogenic 929755 GRCh37: 7:99795404-99795404
GRCh38: 7:100197781-100197781
17 JAK2 , INSL6 NM_004972.4(JAK2):c.436G>A (p.Asp146Asn) SNV Pathogenic 929762 GRCh37: 9:5044488-5044488
GRCh38: 9:5044488-5044488
18 GALT NM_000155.4(GALT):c.667C>T (p.Arg223Cys) SNV Pathogenic 529225 rs111033750 GRCh37: 9:34648433-34648433
GRCh38: 9:34648436-34648436
19 overlap with 159 genes GRCh37/hg19 Xq22.1-24(chrX:99931059-120328627)x1 copy number loss Pathogenic 221776 GRCh37: X:99931059-120328627
GRCh38:
20 PEX6 NM_000287.4(PEX6):c.2356C>T (p.Arg786Trp) SNV Pathogenic 553552 rs267608239 GRCh37: 6:42933788-42933788
GRCh38: 6:42966050-42966050
21 ERCC1 NM_001983.4(ERCC1):c.321+61_525+132del Deletion Pathogenic 981245 GRCh37: 19:45922224-45924375
GRCh38: 19:45418966-45421117
22 CHEK2 NM_007194.4(CHEK2):c.1169A>C (p.Tyr390Ser) SNV Pathogenic 141818 rs200928781 GRCh37: 22:29091788-29091788
GRCh38: 22:28695800-28695800
23 PMM2 NM_000303.3(PMM2):c.323C>T (p.Ala108Val) SNV Pathogenic 92800 rs200503569 GRCh37: 16:8900240-8900240
GRCh38: 16:8806383-8806383
24 NTRK1 NM_001007792.1(NTRK1):c.2011G>A (p.Glu671Lys) SNV Likely pathogenic 526718 rs747855434 GRCh37: 1:156849863-156849863
GRCh38: 1:156880071-156880071
25 overlap with 223 genes GRCh37/hg19 Xq25-28(chrX:122757437-155208244)x1 copy number loss Likely pathogenic 625854 GRCh37: X:122757437-155208244
GRCh38:
26 RYR3 NM_001036.5(RYR3):c.3092A>T (p.Lys1031Met) SNV Likely pathogenic 461901 rs753104655 GRCh37: 15:33926851-33926851
GRCh38: 15:33634650-33634650
27 NOTCH2 NM_024408.4(NOTCH2):c.5105G>A (p.Arg1702Gln) SNV Likely pathogenic 929740 GRCh37: 1:120464967-120464967
GRCh38: 1:119922344-119922344
28 WT1 NM_024426.6(WT1):c.1021A>G (p.Ser341Gly) SNV Likely pathogenic 929769 GRCh37: 11:32421586-32421586
GRCh38: 11:32400040-32400040
29 RAD51C NM_058216.3(RAD51C):c.1090A>G (p.Ser364Gly) SNV Likely pathogenic 142585 rs587782565 GRCh37: 17:56811542-56811542
GRCh38: 17:58734181-58734181
30 THBS1 NM_003246.4(THBS1):c.1060C>T (p.Pro354Ser) SNV Likely pathogenic 929776 GRCh37: 15:39877704-39877704
GRCh38: 15:39585503-39585503
31 MIR4713HG , CYP19A1 , PIRC66 NM_000103.4(CYP19A1):c.383A>G (p.His128Arg) SNV Likely pathogenic 887524 GRCh37: 15:51520044-51520044
GRCh38: 15:51227847-51227847
32 BRWD1 NM_033656.4(BRWD1):c.656G>A (p.Arg219His) SNV Likely pathogenic 929785 GRCh37: 21:40665912-40665912
GRCh38: 21:39293986-39293986
33 AFF2 NM_002025.4(AFF2):c.3203C>G (p.Ser1068Trp) SNV Likely pathogenic 929787 GRCh37: X:148048609-148048609
GRCh38: X:148967079-148967079
34 CYP17A1 NM_000102.4(CYP17A1):c.644T>G (p.Val215Gly) SNV Likely pathogenic 929767 GRCh37: 10:104594564-104594564
GRCh38: 10:102834807-102834807
35 ZNF462 NM_021224.6(ZNF462):c.3515C>G (p.Pro1172Arg) SNV Likely pathogenic 929764 GRCh37: 9:109689708-109689708
GRCh38: 9:106927427-106927427
36 MLH3 NM_001040108.2(MLH3):c.1387A>C (p.Ser463Arg) SNV Likely pathogenic 836477 GRCh37: 14:75514972-75514972
GRCh38: 14:75048269-75048269
37 BNC1 NM_001717.4(BNC1):c.2273C>T (p.Thr758Ile) SNV Likely pathogenic 929778 GRCh37: 15:83931730-83931730
GRCh38: 15:83262978-83262978
38 POLG NM_002693.3(POLG):c.1685G>A (p.Arg562Gln) SNV Likely pathogenic 929779 GRCh37: 15:89869870-89869870
GRCh38: 15:89326639-89326639
39 SH2B1 NM_015503.2(SH2B1):c.1846T>C (p.Ser616Pro) SNV Likely pathogenic 929780 GRCh37: 16:28883975-28883975
GRCh38: 16:28872654-28872654
40 FANCA NM_000135.4(FANCA):c.3665C>T (p.Pro1222Leu) SNV Likely pathogenic 929781 GRCh37: 16:89809308-89809308
GRCh38: 16:89742900-89742900
41 SIRT6 NM_016539.4(SIRT6):c.362G>A (p.Arg121His) SNV Likely pathogenic 929782 GRCh37: 19:4179116-4179116
GRCh38: 19:4179119-4179119
42 ADAMTS1 NM_006988.5(ADAMTS1):c.1304C>A (p.Ser435Tyr) SNV Likely pathogenic 929783 GRCh37: 21:28213391-28213391
GRCh38: 21:26841072-26841072
43 MND1 GRCh37/hg19 4q31.3(chr4:154316483-154325120) copy number loss Likely pathogenic 812128 GRCh37: 4:154316483-154325120
GRCh38:
44 IGF2R NM_000876.4(IGF2R):c.451C>T (p.His151Tyr) SNV Likely pathogenic 929753 GRCh37: 6:160431755-160431755
GRCh38: 6:160010723-160010723
45 POR NM_000941.3(POR):c.1588C>T (p.Pro530Ser) SNV Likely pathogenic 929754 GRCh37: 7:75615086-75615086
GRCh38: 7:75985768-75985768
46 KHDRBS1 NM_006559.3(KHDRBS1):c.1262C>T (p.Pro421Leu) SNV Likely pathogenic 929733 GRCh37: 1:32508155-32508155
GRCh38: 1:32042554-32042554
47 DMRT3 NM_021240.4(DMRT3):c.1327C>T (p.Pro443Ser) SNV Likely pathogenic 929761 GRCh37: 9:990913-990913
GRCh38: 9:990913-990913
48 NOBOX NM_001080413.3(NOBOX):c.1440G>C (p.Lys480Asn) SNV Likely pathogenic 929756 GRCh37: 7:144096072-144096072
GRCh38: 7:144398979-144398979
49 NOS3 NM_000603.5(NOS3):c.172C>T (p.Pro58Ser) SNV Likely pathogenic 929757 GRCh37: 7:150692304-150692304
GRCh38: 7:150995216-150995216
50 NOS3 NM_000603.5(NOS3):c.505G>A (p.Glu169Lys) SNV Likely pathogenic 929758 GRCh37: 7:150693936-150693936
GRCh38: 7:150996848-150996848

Copy number variations for Premature Menopause from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 257158 X 1 4300000 Duplication PRKX Premature ovarian failure
2 258989 X 129800000 154913754 Copy number Premature ovarian failure
3 261305 X 17100000 56600000 Copy number Premature ovarian failure
4 265094 X 73800000 76000000 Duplication ABCB7 Premature ovarian failure
5 265095 X 73800000 76000000 Duplication ZDHHC15 Premature ovarian failure
6 265096 X 73800000 84500000 Copy number Premature ovarian failure
7 255082 9 72339785 73251640 Duplication TRPM3 Primary ovarian insufficiency

Expression for Premature Menopause

Search GEO for disease gene expression data for Premature Menopause.

Pathways for Premature Menopause

Pathways related to Premature Menopause according to KEGG:

36
# Name Kegg Source Accession
1 Ovarian steroidogenesis hsa04913

Pathways related to Premature Menopause according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.57 TP63 RAD54L POLG NBN ERCC1 CHEK2

GO Terms for Premature Menopause

Biological processes related to Premature Menopause according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.88 TP63 STAG3 SGO2 NBN CHEK2
2 cellular response to DNA damage stimulus GO:0006974 9.72 TP63 RAD54L NBN ERCC1 CHEK2
3 regulation of signal transduction by p53 class mediator GO:1901796 9.67 TP63 NBN CHEK2
4 multicellular organism aging GO:0010259 9.46 TP63 ERCC1
5 replicative senescence GO:0090399 9.43 ERCC1 CHEK2
6 isotype switching GO:0045190 9.4 NBN ERCC1
7 t-circle formation GO:0090656 9.37 NBN ERCC1
8 signal transduction in response to DNA damage GO:0042770 9.26 NBN CHEK2
9 double-strand break repair GO:0006302 9.26 RAD54L NBN ERCC1 CHEK2
10 meiotic mismatch repair GO:0000710 9.16 MSH4 ERCC1
11 meiotic cell cycle GO:0051321 9.1 STAG3 SGO2 RAD54L NBN MSH4 BRDT

Molecular functions related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 damaged DNA binding GO:0003684 8.8 TP63 NBN ERCC1

Sources for Premature Menopause

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....